Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma

Learn more about:
Related Clinical Trial
Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care Prospective Evaluation of Biliary Tissue Sampling With ERCP Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture Liver Cancer Registry Platform Target Rare Cancer Knowledge Neoadjuvant Therapy in Biliary Adenocarcinoma BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Efficacy of Fistulotomy for Biliary Cannulation A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Etomidate vs. Midazolam for Sedation During ERCP Loop-tipped Guidewire in Selective Biliary Cannulation Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm BKM120 in Cancers With PIK3CA Activating Mutations A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT PTFE Stents for Treatment of Malignant Biliary Strictures Irreversible Electroporation of Unresectable Liver Tumors Personal Resilience Empowerment Program Study Radiofrequency Ablation for Biliopancreatic Malignancy Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer In Vitro Models of Liver and Pancreatic Cancer Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Evaluation of Stereotactic Radiosurgery For Liver Malignancies Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD Margin Status After Pancreaticoduodenectomy for Cancer A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer A Study of TRK-950 in Patients With Advanced Solid Tumors Combined HCC-MFCCC Proton Therapy and Bevacizumab for Primary Liver Tumors Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Fluorescence QRH-882260 Peptide Imaging in the Bile Duct A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer MRCP Diagnoses EHCC Better When Combined DWI Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Comparison of Biliary Forceps Biopsy and Brush Cytology Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Endobiliary RFA for Unresectable Malignant Biliary Strictures A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Clinical Effect and Safety of PDT and RFA for Unresectable EHCC Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Trial of IRE in Cholangiocarcinoma Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Study of Pembrolizumab and Olaparib in Bile Duct Cancer Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma ncRNAs in Exosomes of Cholangiocarcinoma Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Brief Title

Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma

Official Title

A Phase II Single Arm Study to Evaluate the Safety and Efficacy of RAD001 as Monotherapy in Treatment naïve Advanced Cholangiocarcinoma

Brief Summary

      The purpose of this study is to determine whether everolimus is effective in the treatment of
      patients with advance cholangiocarcinoma.
    

Detailed Description

      Cholangiocarcinoma is one of the most common cause of cancer death in Thailand. Patients with
      cholangiocarcinoma are often diagnosed at advanced stage. Palliative therapeutic approaches
      consisting of percutaneous and endoscopic biliary drainage have usually been used for these
      patients, since there is no effective chemotherapeutic treatment for this type of cancer.
      Activation of the phosphoinositide-3-kinase (PI3K)/Akt/mTOR signaling pathway is frequently
      found in cholangiocarcinoma cells. It has been suggested to be a key step leading to the
      progression of cholangiocarcinoma. In this study, the investigators hypothesize that
      inhibition of mTOR may be useful in treating cholangiocarcinoma.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

progression free survival in cholangiocarcinoma patients whom treated with everolimus

Secondary Outcome

 overall survival rate

Condition

Cholangiocarcinoma

Intervention

Everolimus

Study Arms / Comparison Groups

 RAD001
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

40

Start Date

January 2012

Completion Date

June 2014

Primary Completion Date

December 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Histologic confirmed diagnosis of cholangiocarcinoma.

          -  Patients must present with disease not amenable to curative surgery.

          -  ECOG performance status of < 2

          -  Patients with at least one measurable lesion at baseline as per the RECIST criteria.

          -  The following laboratory parameters at screening (visit 1):

        WBC are equal to or more than 3,000/uL. Platelet are equal to or more than 100,000/uL
        Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN. Patients with
        known liver metastases: AST and ALT ≤ 5 x ULN Total Bilirubin < 2 mg/dl* (after drainage)
        Serum creatinine equal to or less than 2.0 x upper normal limit

          -  Life expectancy equal to or more than 12 weeks.

          -  Ability to understand and willingness to sign a written informed consent and to be
             able to follow the visit schedule.

          -  Female patients at child-bearing age must have negative pregnancy test.

          -  Patients refuse to have treatment with Chemotherapy or Radiation.

        Exclusion Criteria:

          -  Patients within 2 weeks post-minor surgery, 4 weeks post-major surgery to avoid wound
             healing complications. Percutaneous biopsies require no waiting time prior to study
             entry.

          -  Patients with a recent history of hemoptysis, ≥ 0.5 teaspoon of red blood.

          -  Patients who have received prior systemic treatment for their metastatic
             cholangiocarcinoma.

          -  Presence of clinically relevant ascites or liver failure.

          -  Patients with extensive symptomatic fibrosis of the lungs.

          -  Patients with a known hypersensitivity to RAD001 (everolimus).

          -  Patients who have previously received mTOR inhibitors (sirolimus, temsirolimus,
             everolimus, deforolimus).

          -  History or clinical evidence of central nervous system (CNS) metastases. Note:
             Subjects who have previously-treated CNS metastases (surgery±radiotherapy,
             radiosurgery, or gamma knife) and meet all 3 of the following criteria are eligible:

        Are asymptomatic Have had no evidence of active CNS metastases for ≥ 6 months prior to
        enrollment and Have no requirement for steroids or enzyme-inducing anticonvulsants (EIAC)

          -  Clinically significant gastrointestinal abnormalities including, but not limited to:

        Malabsorption syndrome Major resection of the stomach or small bowel that could affect the
        absorption of RAD001 Active peptic ulcer disease Inflammatory bowel disease Ulcerative
        colitis, or other gastrointestinal conditions with increased risk of perforation History of
        abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days
        prior to beginning of study treatment;

          -  Patients receiving chronic systemic treatment with corticosteroids or another
             immunosuppressive agent. Inhaled and topical steroids are acceptable

          -  Patients with a known history of human immunodeficiency virus seropositivity

          -  Patients with autoimmune hepatitis

          -  Patients with an active, bleeding diathesis. Patients may use coumadin or heparin
             preparations.

          -  Patients who have any severe and/or uncontrolled medical conditions or other
             conditions that could affect their participation in the study.

          -  Patients who have a history of another primary malignancy ≤ 3 years, with the
             exception of non-melanoma skin cancer and carcinoma in situ of uterine.

          -  Female patients who are pregnant or breastfeeding, or adults of reproductive potential
             who are not using effective birth control methods.

          -  Patients who are using other investigational agents or who had received
             investigational drugs ≤ 4 weeks prior to study treatment start.

          -  Patients unwilling or unable to comply with the protocol.

          -  Patient who will have got benefit from Radiation or Chemotherapy.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Kawin Leelawat, MD, PhD, , 



Administrative Informations


NCT ID

NCT01525719

Organization ID

R-53326


Responsible Party

Principal Investigator

Study Sponsor

Ratchavithi Hospital


Study Sponsor

Kawin Leelawat, MD, PhD, Principal Investigator, Rajavithi Hospital


Verification Date

January 2012